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The 3.2-Å resolution structure of human mTORC2
Alain Scaiola1*, Francesca Mangia2*, Stefan Imseng2, Daniel Boehringer3, Karolin Berneiser2, 
Mitsugu Shimobayashi2, Edward Stuttfeld2, Michael N. Hall2, Nenad Ban1†, Timm Maier2†
The protein kinase mammalian target of rapamycin (mTOR) is the central regulator of cell growth. Aberrant mTOR 
signaling is linked to cancer, diabetes, and neurological disorders. mTOR exerts its functions in two distinct multi-
protein complexes, mTORC1 and mTORC2. Here, we report a 3.2-Å resolution cryo-EM reconstruction of mTORC2. 
It reveals entangled folds of the defining Rictor and the substrate-binding SIN1 subunits, identifies the carboxyl- 
terminal domain of Rictor as the source of the rapamycin insensitivity of mTORC2, and resolves mechanisms for 
mTORC2 regulation by complex destabilization. Two previously uncharacterized small-molecule binding sites are 
visualized, an inositol hexakisphosphate (InsP6) pocket in mTOR and an mTORC2-specific nucleotide binding site 
in Rictor, which also forms a zinc finger. Structural and biochemical analyses suggest that InsP6 and nucleotide 
binding do not control mTORC2 activity directly but rather have roles in folding or ternary interactions. These 
insights provide a firm basis for studying mTORC2 signaling and for developing mTORC2-specific inhibitors.
INTRODUCTION
The serine/threonine kinase mammalian target of rapamycin (mTOR), 
a phosphatidylinositol 3-kinase–related kinase (PIKK) (1–3), controls 
cell growth by balancing anabolic and catabolic metabolism (1, 4). 
mTOR is found in two separate complexes: mTOR complex 1 (mTORC1) 
and mTORC2 (1, 5). mTORC1 consists of mTOR, regulatory-associated 
protein of mTOR (Raptor), and mammalian homolog of protein lethal 
with sec thirteen protein 8 (mLST8) (5–7). mTORC2 comprises 
mTOR, rapamycin-insensitive companion of mTOR (Rictor) (8), 
stress-activated map kinase-interacting protein 1 (SIN1) (9), and 
mLST8 (8), and associates with the facultative subunit protein ob-
served with Rictor-1/2 (Protor-1/2) (10). mTORC2 is activated by 
insulin and phosphoinositide 3-kinase (PI3K) signaling (1) and acts 
on cell survival and proliferation (4) by phosphoryl ating the AGC 
family kinases: AKT, PKC, and SGK (1, 4, 11–13). mTORC2 also 
promotes tumorigenesis via up-regulation of lipid biosynthesis (14).
mTOR inhibitors played a major role in the elucidation of mTOR 
signaling and are used in cancer treatment (15). The polyketide rapa-
mycin specifically inhibits mTORC1 (6) by forming a complex with the 
cellular protein FKBP12 that then binds the FKBP-rapamycin binding 
(FRB) domain in mTOR (Fig. 1A) (16). Adenosine 5′- triphosphate 
(ATP)–like inhibitors target the ATP-binding site in the kinase cat-
alytic domain of the mTORCs (Fig. 1A) or the structurally related PI3K 
(17). Recently, mTORC2-selective inhibitors were identified, but their 
mechanism of action remains unknown (18). Several intermediate- 
resolution reconstructions of (m)TOR complexes (16, 19–22) and 
high- resolution reconstructions of human mTORC1 (23) have been 
reported, but no high-resolution information on mTORC2 is avail-
able. Of the mTORC2 accessory proteins, only the isolated pleck-
strin homology (PH) and conserved region in the middle (CRIM) 
domains of SIN1 have been structurally characterized (24–26). For 
Rictor, fold- and secondary structure–based models have been pro-
posed based on intermediate-resolution cryo–electron microscopy 
(cryo-EM) reconstructions (20–22).
RESULTS
Structure determination of mTORC2 by cryo-EM
To investigate the structure of mTORC2 and the mechanism of its 
regulation, we coexpressed recombinant components of human 
mTORC2 (mTOR, mLST8, Rictor, and SIN1) in Spodoptera frugiperda 
cells. The assembled complex, purified using tag-directed antibody 
affinity followed by size exclusion chromatography, was analyzed 
by cryo-EM (Fig. 1B and figs. S1, A to C, and S2) in the presence of 
ATPS and either the full-length substrate Akt1 (fig. S1, D and E) or 
an Akt1 variant missing the PH domain (PH-Akt1), or in the 
absence of Akt1 with and without ATPS (fig. S2). The sample pre-
pared in the presence of ATPS and PH-Akt1 yielded the highest 
overall resolution of 3.2 Å (density A in fig. S2).
mTORC2 forms a rhomboid-shaped dimer (Fig. 1C) as observed 
in lower-resolution mTORC2 reconstructions (20–22). The mTOR 
kinase consists of the N-terminal “Horn” and “Bridge” domains 
followed by the FAT, FRB, and kinase domains (Fig. 1A). mTOR 
forms the core of mTORC2 with mLST8 on the periphery, close to 
the active site cleft, similar to mTOR-mLST8 in mTORC1 (16, 23). 
In the overall reconstruction, as a consequence of EM refinement of 
a flexible molecule, one-half of the dimer showed better local reso-
lution (Fig. 1B, fig. S3, A to C, and movie S1). Therefore, focused 
refinement on a unique half of the assembly improved the resolu-
tion to 3.0 Å (density C in fig. S2), and these maps were used for 
structural modeling (fig. S3, D to F). Previous mTORC2 and yeast 
TORC2 reconstructions (20–22) revealed that the two mTOR FAT 
domains are in closer proximity to each other than observed in 
mTORC1 (16, 23, 27), and in the current structure, the distance be-
tween the mTOR FAT domains is further reduced (fig. S3G). Irre-
spective of these structural differences between the two mTORCs, 
the catalytic site in mTORC2 closely resembles the catalytic site in 
mTORC1 without Rheb-mediated activation (23), suggesting that 
mTORC2 may be activated by a yet to be defined mechanism.
The characteristic mTORC2 subunit Rictor blocks 
the rapamycin binding site
Previous studies of mTORC2 subunits Rictor and SIN1 or their yeast 
orthologs were not of sufficient resolution to allow de novo model 
building, resulting in ambiguous or inconsistent interpretations 
(20, 22, 28). Here, we unambiguously model all structured regions 
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of Rictor and the N-terminal region of SIN1 (Fig. 2, A to C), where-
as the middle and C-terminal part of SIN1 retain high flexibility and 
are not resolved. The fold of Rictor differs substantially from previ-
ous interpretations (fig. S3, H and I) (20). Rictor is composed of three 
interacting stacks of -helical repeats, here referred to as the ARM 
domain (AD), the HEAT-like domain (HD), and the C-terminal do-
main (CD) (Fig. 2, A to C). The N-terminal AD (residues 26 to 487) 
forms a large superhelical arrangement of nine ARM repeats (Fig. 2, 
A and B) that structurally separates the HD and CD. The HD (resi-
dues 526 to 1007), interpreted as two separate domains in previous 
lower-resolution studies (20, 22), is composed of 10 HEAT-like re-
peats. In sequence space, the HD and CD of Rictor are separated by 
an extended stretch of residues (1008 to 1559) that are predicted to 
be disordered and are not resolved in our reconstruction. We refer 
to this region as the phosphorylation site region (PR) because it 
contains most of Rictor’s phosphorylation sites (29). The two ends of 
the PR are anchored by a two-stranded -sheet at the top of the HD, 
which is thus termed the PR anchor (Fig. 2, B and C, and fig. S4A). 
From here, a partially flexible linker wraps around the AD and the 
mTOR FRB domain extending toward the CD (Fig. 2B and fig. S4C).
The structured parts of the CD form a four-helix bundle and a 
zinc finger, with bound Zn2+, in the vicinity of the Rictor N termi-
nus (Fig. 2A and fig. S4, B and C). Residues coordinating the zinc 
ion are highly conserved in metazoan Rictor (fig. S4F). In earlier 
work, this domain had been interpreted as representing the SIN1 
domain (20). The complete CD is absent in sequences of fungal 
Rictor orthologs, but other large extensions in yeast Rictor and 
SIN1 sequences may occupy the equivalent location in yeast TORC2, 
as observed in an intermediate-resolution reconstruction of bud-
ding yeast TORC2 (fig. S4, D and E) (21). Increased levels of Zn2+ 
have been reported to stimulate Akt1 S473 phosphorylation in cells 
(30, 31), but no direct involvement of mTORC2 activation has been 
demonstrated.
Contacts between Rictor and mTOR are made by the Rictor AD, 
which sits between the Horn domain of the proximal mTOR sub-
unit and the Bridge domain of the distal mTOR subunit (Fig. 2B). 
With its positioning on top of the mTOR FRB domain, the CD of 
Rictor blocks the binding space of FKBP12-rapamycin in mTORC1, 
thereby explaining the absence of an mTORC1-like mode of sensi-
tivity to rapamycin for mTORC2 (Fig. 2D) (5, 8, 28).
Fig. 2. The architecture of Rictor. (A) Sequence-level domain organization of 
Rictor. Flexible and unresolved regions are indicated as dotted lines. Interactions 
with other proteins in the complex are highlighted below the sequences. Asterisks 
indicate residues interacting with the N-terminal region of SIN1. (B) Two views of 
Rictor, colored by domains. The structured part of Rictor forms three domains: an 
N-terminal Armadillo repeat domain (AD, magenta), a HEAT-like repeat domain 
(HD, dark magenta), and a C-terminal domain (CD, light red); the phosphorylation 
site region (PR) remains disordered. The sequences flanking the nonresolved PR 
are highlighted in red, and the PR anchor is colored in gold. Bound ligands are 
shown as cyan spheres. (C) Schematic representation of Rictor and SIN1 domain 
topology. (D) The Rictor CD occupies the FRB domain and sterically blocks FKBP- 
rapamycin binding (26).
Fig. 1. Structure of mTOR complex 2. (A) Sequence-level domain organization of 
mTOR. Modeled and unresolved regions are indicated as dotted lines. Interactions 
with other proteins in the complex are highlighted below the sequences. (B) Den-
sity of the overall cryo-EM reconstruction of mTORC2 colored according to protein 
subunits and mTOR domains as indicated. The top half is better resolved than the 
lower one, most likely due to conformational flexibility. (C) Cartoon representation 
of mTORC2 in three different orientations. The proteins Rictor (magenta) and SIN1 
(green) are unique to mTORC2, while mTOR (colored by domain) and mLST8 
(orange) are common to both mTORC1 and mTORC2. Bound ligands are repre-
sented as cyan spheres.
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SIN1 integrates its N terminus into Rictor and links Rictor 
to mLST8
The SIN1 subunit of mTORC2 exhibits an unexpected structural 
organization. The N-terminal region (residues 2 to 137), contrary to 
earlier interpretations, does not form an independently folding 
domain but interacts tightly with Rictor and mLST8 in an extended 
conformation (Figs. 2, A to C, and 3, A to E). The CRIM, Ras-binding 
domain (RBD), and PH domains of SIN1, however, remain flexibly 
disposed. The N terminus of SIN1 is inserted into a deep cleft at the 
interface of the AD and HD of Rictor. The N-terminal Ala2 with a 
structurally resolved acetylated N terminus and Phe3 of SIN1 are 
buried in a hydrophobic pocket of Rictor (Fig. 3, C and D, and 
fig. S5A). The anchored N-terminal region of SIN1 forms two short 
helices (residues 6 to 33) inserted into grooves on the surface of the 
Rictor AD (Fig. 3D) and then continues with a flexible sequence 
segment toward the Rictor CD (Figs. 2, B and C, and 3C and fig. S5B). 
Protruding from the Rictor CD, SIN1 forms a helical segment, re-
ferred to as the “traverse,” that spans the distance to mLST8 across 
the mTORC2 kinase cleft (Fig. 3C and fig. S5, B and C). The next 
region of SIN1 interacts with the fourth strand of the second blade 
of the mLST8 propeller by -strand complementation, leading to 
displacement of an mLST8 loop relative to the structure of mLST8 in 
mTORC1 (Fig. 3, C and E, and fig. S5D). SIN1 then follows the 
surface of the mLST8 propeller, finally forming an -helix anchored 
between the first and seventh blades of mLST8.
SIN1 integrates into the Rictor fold and connects Rictor with 
mLST8, suggesting a direct role in stabilizing mTORC2. To test 
the relevance of the anchoring of the N terminus of SIN1 on Rictor, 
we extended the N terminus of SIN1 using tryptophan or arginine 
residues to exploit steric hindrance or charge-charge repulsion to 
prevent the insertion into the Rictor pocket. Insertion of residues 
impairs critical interactions observed for the acetylated N terminus 
of SIN1 and prevents Rictor integration into mTORC2, as observed 
in baculovirus-mediated expression of mTOR components followed 
by pull-down assays (Fig. 3B and fig. S5E). Therefore, SIN1 acts as 
an integral part of the Rictor structure that critically stabilizes inter-
domain interactions, explaining the difficulties observed in purify-
ing isolated Rictor (20).
These observations are also consistent with the locations of post-
translational modifications or mutations that affect mTORC2 activity. 
SIN1 phosphorylation at Thr86 and Thr398 has been reported to 
reduce mTORC2 integrity and kinase activity toward Akt1 Ser473 
(32). Thr86 in SIN1, which is a target for phosphorylation by S6 
kinase (32), is bound to a negatively charged pocket of the Rictor 
CD (Fig. 3C and fig. S5C). Phosphorylation of Thr86 would lead to 
repulsion from this pocket, destabilizing the interaction between 
Rictor and mTOR-mLST8 and presumably the entire mTORC2 as-
sembly, in agreement with earlier in vivo and in vitro observations 
(32). The importance of SIN1 in connecting Rictor to mLST8, and 
therefore also indirectly to mTOR, is also consistent with the re-
quirement of mLST8 for mTORC2 integrity (33, 34).
SIN1 mobile domains are positioned for  
substrate recruitment
A poorly resolved density linked to the SIN1 helix anchored to 
mLST8 is observed in all reconstructions. In previous structural 
studies of yeast TORC2, a similar region of density was associated 
with the CRIM domain of Avo1, the yeast SIN1 ortholog (21, 28). 
Most likely, it represents the mobile substrate-binding CRIM domain 
that directly follows the helix in the SIN1 sequence and has a match-
ing shape based on the solution structure of the Schizosaccharomyces 
pombe SIN1 CRIM domain (Fig. 3F and fig. S6, A to C) (25, 26). The 
positions of the SIN1 RBD and PH domains remain unresolved. In 
the dataset collected for samples with added full-length Akt1 (dataset 
2 in fig. S2), we observed additional low-resolution density (Fig. 3F 
and fig. S6, B and C) between the hypothetic CRIM domain and 
Fig. 3. The SIN1 N-terminal region is an integral component of mTORC2. 
(A) Sequence-level domain organization of SIN1. Flexible and unresolved regions 
are shown above each domain representation as dotted lines in two colors as in-
dicated. Interactions with other proteins in the complex are indicated below the 
domain representation. (B) Extension of the processed SIN1 N terminus disrupts 
assembly of Rictor and SIN1 with mTOR/mLST8 into mTORC2. SDS-polyacrylamide 
gel of a FLAG bead pulldown from lysates of insect cells expressing mTORC2 com-
prising SIN1 variants. Levels of Rictor are drastically reduced in the mTOR-based 
pulldown for mTORC2 carrying variants of SIN1 N-terminally extended by a trypto-
phan (mTORC2 SIN1_W), two consecutive arginines (mTORC2 SIN1_2R), and three 
consecutive arginines (mTORC2 SIN1_3R). (C) Surface representation of mTORC2. 
SIN1 (shown as green cartoon) interacts via two N-terminal helices with Rictor, 
winds around Rictor, traverses the catalytic site cleft, and winds around mLST8. The 
field of view of subpanel D is indicated. (D) Close-up view of the SIN1 N-terminal 
residues, which are deeply inserted between Rictor AD and HD. Acetylated Ala2 
and Phe3 are bound in a hydrophobic pocket, while Asp5 interacts via salt bridges 
(yellow dashes). (E) Top view of mLST8 -propeller (orange) and the interaction 
regions with SIN1 (green). The nomenclature for WD40 -propeller repeats is indi-
cated. (F) Top view of the catalytic site with the structure shown as surface together 
with the density of a subclass (light gray). The lower-resolution extra density is 
consistent with a placement of the SIN1 CRIM domain, here shown in dark green 
(PDB: 2RVK). Unassigned extra density protrudes from the CRIM domain to the 
mTOR active site and Rictor.
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Rictor AD and CD in the vicinity of the mTOR active site. This 
density, not of sufficient resolution to assign specific interactions, 
may represent parts of bound Akt1 or SIN1 domains (fig. S6C).
A proposed regulatory mechanism for mTORC2 involves ubiqui-
tylation of mLST8 on Lys305 and Lys313 (35). Loss of ubiquitylation 
by K305R and/or K313R mutation, or truncation of mLST8 at 
Tyr297, leads to mTORC2 hyperactivation and increased AKT phos-
phorylation (35). mLST8 Lys305 is proximal to the SIN1 helix an-
choring the CRIM domain. Ubiquitylation of Lys305 would prevent 
association of the SIN1 helix, leading to dislocation of the SIN1 
CRIM domain required for substrate recruitment (Figs. 3C and 4A). 
Ubiquitylation of Lys313, which is found on the lower face of mLST8 
(Figs. 3C and 4A), presumably also interferes with positioning of 
the CRIM domain (fig. S6A).
Two small-molecule binding sites outside the mTOR kinase 
catalytic region are occupied with ATP and IP6
We observed two previously uncharacterized, small-molecule bind-
ing sites outside the mTOR catalytic site, which is itself occupied 
by ATPS. The first (A-site) (Fig. 4B and fig. S7, A and B) is located 
in the HD of Rictor and is thus specific to mTORC2. The second 
(I-site) (Fig. 4C and fig. S7C) is located in the FAT domain of mTOR 
and is thus common to mTORC1 and mTORC2.
The density of the small molecule in the A-site matched that of 
an ATP molecule and was confirmed to be ATP (or ATPS) through 
a comparison of cryo-EM reconstructions of mTORC2 with and 
without ATPS added at a near physiological concentration of 2 mM 
(datasets 1 and 4, figs. S2 and S7A). The A-site does not resemble 
any known ATP-binding site. Positively charged amino acids (Lys541, 
Arg575, Arg576, and Arg572) of the A-site are conserved in Rictor 
orthologs from yeast to human (figs. S4E and S8). Other residues 
are not conserved, hinting at the possibility for interactions with 
alternative negatively charged ligands. The A-site is located approx-
imately 100 Å from the mTOR catalytic site. Ligand binding to the 
A-site caused neither long-range allosteric change affecting the 
kinase site nor local structural perturbations (fig. S9, I to L).
To investigate the effect of ligand binding to the A-site, we gen-
erated a series of Rictor variants with a mutated A-site (table S1). 
Variants with three or four mutated residues (A3 and A4) assem-
bled into mTORC2 (fig. S10B), while variant A5 was defective in 
assembly (fig. S10, B to D). Cryo-EM reconstructions of variants A3 
and A4 in the presence of ATPS (fig. S9, I to L) confirmed that the 
chosen mutations abolish ligand binding under near physiological 
conditions (figs. S7A and S9, J and L). Purified mTORC2 containing 
Rictor variant A3 or A4 exhibited thermal stability and kinase activity, 
in an Akt1 in vitro phosphorylation assay, comparable to wild-type 
(WT) mTORC2 (fig. S10, F to H). Complementation of a Rictor knock-
out (KO) in human embryonic kidney (HEK) 293T cells by transfected 
Rictor-WT, or Rictor variant A3 yielded comparable levels of Akt1-S473 
phosphorylation (table S1 and fig. S11). Together, the above analyses 
indicate that ligand binding to the A-site does not directly influ-
ence mTORC2 kinase activity, suggesting rather a role in the inter-
action with other, yet unidentified, partner proteins of mTORC2.
The I-site is formed entirely by the FAT domain of mTOR, where 
a large, positively charged, pocket is lined by six lysine and two 
arginine residues to bind an extended ligand (Fig. 4C and fig. S7C). 
The I-site was still partially occupied in our reconstruction of 
mTORC2 prepared without addition of exogenous ATPS or other 
relevant ligands (fig. S7A). The copurified molecule was identified 
by map appearance and by ion mobility spectrometry–mass spec-
trometry (IMS-MS) as inositol hexakisphosphate (InsP6) (figs. S7, 
D to F, and S12). InsP6 binds in a region, which is incomplete in 
related PI3Ks (36), but is generally conserved in members of the 
PIKK family of kinases (37). InsP6 was previously reported to asso-
ciate with DNA-PKcs (38). Recently, structure determination of the 
PIKK family kinase SMG1 revealed InsP6 binding in a region corre-
sponding to the I-site and led the authors to postulate a correspond-
ing binding site in mTOR but involving both the kinase domain and 
FAT domain (37). InsP6 has previously been observed as a structural 
component of multi-subunit assemblies, including the spliceosome 
(39) and proteasome activator complex (40), and helical repeat 
regions have been identified as InsP6 interaction sites (41).
To investigate the function of InsP6 interaction, we purified re-
combinant mTORC2 containing mTOR I-site mutations (table S1). 
mTOR variants with two and three mutations, I2 and I3, yielded 
intact mTORC2 complexes (fig. S10A), while a variant with five 
mutations, I5, failed to assemble into mTORC2 (fig. S10, A and D). 
mTORC2 containing mTOR variants I2 and I3 displayed normal 
Fig. 4. Small-molecule binding sites of mTORC2 outside the active site region. 
(A) Overview of mTORC2 architecture and ligand interaction sites. Each half of the 
dimeric mTORC2 has three small-molecule binding sites. The kinase active site and 
the A-site, which is located in the peripheral region of Rictor, bind to ATP (or ATP 
analogs). The I-site in the middle of the FAT domain of mTOR binds InsP6. The indi-
cated modifications on SIN1 and mLST8 affect mTORC2 assembly. Extra-density 
region following the CRIM domain is indicated as a gray outline. (B). Close-up view 
of the A-site on the periphery of the Rictor HD with bound ATPS. A hydrogen bond 
between ATPS and Asn543 is shown as dashed yellow lines. (C) Close-up view of 
the I-site in the FAT domain of mTOR. InsP6 is surrounded by a cluster of positively 
charged amino acids. It only directly interacts with residues of the FAT domain.
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kinase activity toward Akt1 in vitro (fig. S10E). Notably, the muta-
tions in I2 are equivalent to those reported previously to abolish 
completely the kinase activity of an N-terminally truncated “naked” 
mTOR fragment toward a C-terminal peptide of Akt1 (37). A pos-
sible explanation for this apparent discrepancy is provided by a re-
duced stability of mTORC2 assembled using the I2 variant (but not 
the I3 variant) (fig. S10G). This destabilizing effect might be more 
pronounced in an mTOR fragment than in the context of an assem-
bled mTORC2 (fig. S10G).
To investigate a possible role of InsP6 metabolism on mTORC2 
activity in HEK293T cells, we knocked down (KD) and knocked 
out (KO) inositol-pentakisphosphate 2-kinase (IPPK) and multiple 
inositol polyphosphate phosphatase 1 (MINPP1), respectively. The 
former enzyme generates InsP6, whereas the latter degrades it 
(fig. S13). These manipulations of InsP6-metabolizing enzymes did 
not alter mTORC2 kinase activity in nonstimulated cells or in cells 
stimulated with fetal calf serum (FCS) and insulin (fig. S13). These 
biochemical results are consistent with the observed stable binding 
of InsP6 to mTORC2 and suggest a role of InsP6 in mTOR folding 
or mTOR complex assembly, rather than as an acute transient 
metabolic input signal to mTORC1 or mTORC2.
DISCUSSION
Here, we describe a bona fide structure of mTORC2. We visualized 
how SIN1 stabilizes and tethers Rictor to the mTOR-mLST8 core. 
SIN1 further uses mLST8 as a platform for positioning its substrate- 
recruiting CRIM domain, revealing a new functional role for mLST8 
and rationalizing the impact of SIN1 and mLST8 modifications on 
mTORC2 activity. We also provide the structural basis for how the 
Rictor CD determines mTORC2’s rapamycin insensitivity, by a 
mechanism different from those inferred from previous structural 
data (20, 22). We identified and functionally characterized two 
ligand binding sites in mTORC2. The I-site in mTOR is common 
to mTORC1 and mTORC2, binds InsP6, and presumably functions 
in mTOR folding or assembly rather than acting as a sensor site 
for acute changes in cellular InsP6 concentration. The mTORC2- 
specific A-site of Rictor binds ATP. It does not affect mTORC2 
activity by allostery but may be involved in linking partner protein 
interactions to cellular nucleotide triphosphate concentrations. 
Together, the data presented here provide a firm basis for further 
analysis of the function of mTORC2 and its interplay with partner 
proteins for controlling subcellular localization and regulation of 
activity (1, 4, 14). Interaction sites of Rictor and mLST8 with SIN1 
provide an opportunity for the development of inhibitors specific 
for mTORC2.
MATERIALS AND METHODS
Protein expression and purification
Insect cell vectors from the “MultiBac” Baculovirus expression system 
(42) (Geneva Biotech, Geneva, Switzerland) have been used to clone 
internally FLAG-tagged pAceBAC-mTOR (FLAG after Asp258), 
pIDK-Rictor, pIDC-mLST8, and pAceBAC1-SIN1 using Gateway 
Cloning (Thermo Fisher Scientific, USA). Rictor was originally 
amplified from myc-Rictor, which was a gift from D. Sabatini (8) 
(Addgene plasmid no. 11367). Site-directed mutagenesis was used 
to generate mTORC2 A- and I-site variants. The following set of 
A-site mutants with pIDK-Rictor as template was created: Rictor_
R572E_R575E_R576E (A3), Rictor_R572E_R575E_R576E_Y579A 
(A4), and Rictor_R572E_R575E_R576E_Y579A_L587W (A5). The 
following I-site mutants with FLAG-tagged pAceBAC-mTOR were 
generated: mTOR_K1753E_K1788E (I2), mTOR_R1628E_K1655E_
K1662E (I3), and mTOR_R1628E_K1655E_K1662E_K1706E_K1735E 
(I5). WT Rictor and mutants A3 and A5 were subcloned into plasmid 
MX01 (Addgene plasmid no. 158624). SIN1 N-terminal variants were 
generated by inserting a tryptophan (SIN1_W), two consecutive 
arginines (SIN1_2R), or three consecutive arginines (SIN1_3R) 
using site-directed mutagenesis and pAceBAC1-SIN1 as template. 
Plasmids encoding FLAG-tagged mTOR, Rictor, and mLST8 were 
fused to a MultiBac expression plasmid using Cre-recombinase 
(New England Biolabs, Ipswich, USA) and transposed into a bacmid 
for baculovirus production. Baculovirus encoding untagged SIN1 
was produced separately.
Sf21 insect cells (Expression Systems) were grown in HyClone 
insect cell media (GE Life Sciences), and baculovirus was generated 
according to Fitzgerald et al. (42). For the expression of recombi-
nant human WT mTORC2, A- and I-site mTORC2 mutants, and 
mTORC2 carrying SIN1 N-terminal variants, Sf21 cells were infected 
at a cell density of 1 Mio/ml. Cells were coinfected with 1:100 (v/v) 
ratio of two undiluted supernatants from cells previously infected 
with baculovirus encoding FLAG-mTOR, Rictor, and mLST8 or 
infected with baculovirus encoding untagged SIN1, respectively. 
WT mTORC2, A-site mutants A3, A4, and A5, and I-site mutants 
I2, I3, and I5 were purified as follows: Insect cells were harvested 
72 hours after infection by centrifugation at 800g for 25 min and 
stored at −80°C until further use. Cell pellets were lysed in 50 mM 
bicine (pH 8.5), 200 mM NaCl, and 2 mM MgCl2 by sonication, and 
the lysate was cleared by ultracentrifugation. Soluble protein was 
incubated with 10 ml of anti-DYKDDDDK agarose beads (Genscript, 
Piscataway, USA) for 1 hour at 4°C. The beads were transferred to a 
50-ml gravity flow column (Bio-Rad) and washed four times with 
200 ml of wash buffer containing 50 mM bicine (pH 8.5), 200 mM 
NaCl, and 2 mM EDTA. Protein was eluted by incubating beads 
for 30 min with 10 ml of wash buffer supplemented with synthetic 
DYKDDDDK peptide (0.6 mg/ml) (Genscript, Piscataway, USA). 
The eluate was combined with three additional elution steps using 
synthetic DYKDDDDK peptide (0.1 mg/ml) and 5-min incubation 
time. The eluted protein was concentrated using a 100,000-Da mo-
lecular mass cutoff centrifugal concentrator (Amicon) of regenerated 
cellulose membrane and purified by size exclusion chromatography 
on a custom-made Superose 6 Increase 10/600 GL gel filtration 
column equilibrated with 10 mM bicine (pH 8.5), 150 mM NaCl, 
0.5 mM EDTA, and 2 mM tris(2-carboxyethyl)phosphine (TCEP). Purified 
WT mTORC2 was concentrated in gel filtration buffer to a final con-
centration of 3 to 3.5 mg/ml determined by A280 absorption using 
NanoDrop 2000 (Thermo Fisher Scientific). Sample was supple-
mented with 5% (v/v) glycerol and stored at −80°C for later cryo-EM 
use. Purified mTORC2 variants with A- and I-site mutants were con-
centrated in gel filtration buffer to a final concentration of 0.4 to 2 mg/ml 
as determined by absorption at 280-nm wavelength using NanoDrop 
2000 (Thermo Fisher Scientific). The resulting samples were supple-
mented with 5% (v/v) glycerol and stored at −80°C for later use.
The coding sequence for Akt1 (43) was cloned into a pAceBAC1 
expression vector (Geneva Biotech, Geneva, Switzerland) with an 
N-terminal His10-Myc-FLAG tag by Gateway cloning. Baculovirus 
was produced as described for mTORC2. Akt1 was purified with 
anti-DYKDDDDK agarose beads as described for mTORC2. The 
 on N
ovem
ber 13, 2020
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
Scaiola et al., Sci. Adv. 2020; 6 : eabc1251     6 November 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
6 of 10
eluted protein was concentrated using a 10,000-Da molecular mass 
cutoff centrifugal concentrator (Amicon) of regenerated cellulose mem-
brane and further purified by size exclusion chromatography with a 
Superdex 75 Increase column equilibrated with 10 mM bicine (pH 8.5), 
150 mM NaCl, 0.5 mM EDTA, and 2 mM TCEP. Purified Akt1 was 
concentrated in gel filtration buffer, supplemented with 5% (v/v) 
glycerol, and stored at −80°C for further experiments. Dephosphoryl-
ated Akt1 was obtained after overnight incubation of 4.5 mg of protein 
with 6 g of -protein phosphatase (New England Biolabs) in the 
presence of PMP buffer (New England Biolabs) and 1 mM MnCl2 
before size exclusion chromatography. Successful Akt1 dephosphoryl-
ation was confirmed by Western blot with antibodies against phospho– 
AKT-Ser473 (no. 4060; Cell Signaling Technology, Beverly, USA) and 
phospho–AKT-Thr450 (no. 9267; Cell Signaling Technology, Beverly, 
USA) at a dilution of 1:1000 in 5 ml of Tris-buffered saline with 0.1% 
Tween20 (TBST). Human (Delta-PH) Akt1 protein (residues 144 
to 480, mono- phosphorylated on T450), as described by Lučić et al. 
(44) (therein referred to as Akt1KD), was provided by T. Leonard 
(Max-Perutz Labs, Vienna).
Expression and assembly analysis via immunoprecipitation
A-site mutants A3, A4, and A5 and I-site mutants I2, I3, and I5, and 
mTORC2 carrying SIN1 N-terminal variants extended by a trypto-
phan (SIN1_W), two consecutive arginines (SIN1_2R), and three 
consecutive arginines (SIN1_3R) inserted between the processed 
Met1 and Ala2, were immunoprecipitated in small scale using FLAG 
beads. Five-gram wet weight of pellets from insect cells expressing 
A- and I-site mutants and SIN1 N-terminal variants was lysed in 
50 mM bicine (pH 8.5), 200 mM NaCl, and 2 mM MgCl2 using a 
Dounce homogenizer. The lysate was cleared by ultracentrifugation 
for 45 min at 35,000g. Soluble protein was incubated with 125 l 
of anti-DYKDDDDK agarose beads (Genscript, Piscataway, USA) 
for 1 hour at 4°C. The beads were transferred to a 5-ml gravity flow 
column (Pierce Centrifuge Columns, Thermo Fisher Scientific) and 
washed with 50 ml of buffer containing 50 mM bicine (pH 8.5), 
200 mM NaCl, and 2 mM EDTA. Protein was eluted by 30-min 
incubation of the beads with 400-l wash buffer supplemented with 
synthetic DYKDDDDK peptide (0.6 mg/ml) (Genscript, Piscataway, 
USA). Total lysate, soluble supernatant after ultracentrifugation, flow 
through from FLAG column, buffer wash, and elution fraction were 
loaded onto a 4 to 15% SDS polyacrylamide gel (Bio-Rad Laboratories). 
In addition, total lysate, supernatant after ultracentrifugation, and 
elution fraction of mTORC2 WT, SIN1 N- terminal variants, and 
mutants A5 and I5 were analyzed by immunoblotting using anti-
bodies against mTOR (no. 2972; Cell Signaling Technology, Beverly, 
USA), SIN1 (A300-910A; Bethyl), Rictor (A300-458A; Bethyl), and 
actin (MAB1501; Merck Millipore) at a dilution of 1:1000 in 5 ml of 
TBST. A goat anti-rabbit horseradish peroxidase (HRP)–labeled 
antibody (ab6721; Abcam, Cambridge, UK) was used as the second-
ary antibody at a dilution of 1:3000 in 5 ml of TBST.
Assay for mTORC2 kinase activity
mTORC2 kinase activity assays were conducted in 100 mM Hepes 
(pH 7.4), 1 mM EGTA, 1 mM TCEP, 0.0025% Tween 20, and 10 mM 
MnCl2 using dephosphorylated Akt1 as a substrate. In a 60-l reac-
tion volume, 0.05 M of either WT or A- and I-site mutant 
mTORC2 was mixed with 1 M Akt1 and, where indicated, either 
dimethyl sulfoxide or 25 M Torin1. The mixture was preincubated 
for 5 min at room temperature, and the reaction was initiated by the 
addition of 10 M ATP. After 20 min at 37°C, the reaction was 
terminated by the addition of 60 l of 2× Laemmli sample buffer. 
The reactions were analyzed by Western blotting using primary 
antibodies against phospho–AKT-Ser473 (no. 4060; Cell Signaling 
Technology, Beverly, USA), phospho–AKT-Thr450 (no. 9267; Cell 
Signaling Technology, Beverly, USA), AKT (no. 4685), and mTOR 
(no. 2972; Cell Signaling Technology, Beverly, USA), anti-FLAG 
antibodies (Sigma-Aldrich, F1804), SIN1 (Bethyl, A300-910A), and 
Rictor (Bethyl, A300-458A) at a dilution of 1:1000 in 5 ml of TBST. 
A goat anti-rabbit HRP-labeled antibody (ab6721; Abcam, Cambridge, 
UK) was used as the secondary antibody at a dilution of 1:3000 in 
5 ml of TBST. Signals were detected using the Enhanced Chemilu-
minescence (ECL) Kit SuperSignal West Femto Maximum Sensitivity 
Substrate (Thermo Fisher Scientific). Images were acquired using a 
Fusion FX (Vilber) imaging system.
Thermal stability assay
Thermal unfolding was monitored by differential scanning fluo-
rimetry (DSF) based on internal tryptophane fluorescence on a Pro-
metheus NT.48 instrument (NanoTemper Technologies). Purified 
WT mTORC2 or mTORC2 containing mutations in A- or I-site 
was diluted to 0.1 mg/ml in 10 mM bicine (pH 8.5), 150 mM NaCl, 
0.5 mM EDTA, and 2 mM TCEP. High-precision capillaries 
(NanoTemper Technologies) were filled with 10-l sample and 
placed on the sample holder. A temperature gradient of 0.1°C/min 
from 22° to 65°C was applied, and fluorescence intensity at 330 and 
350 nm was recorded. A plot of the ratio of fluorescence intensities 
at those wavelengths (F350/F330) was generated using a Python 
script. The experiment was repeated two times with five replicates 
per sample run each time. Melting points were calculated using 
PR.ThermControl software version 2.1.2. Data were analyzed using 
GraphPad Prism version 8.0.0 (GraphPad Software, San Diego, CA, 
USA) to generate the mean and SD of the melting points. One out-
lier, likely resulting from capillary handling, for sample A4 was ex-
cluded from data analysis.
In-cell analysis of mTORC2 activity for A-site mutants
HEK293T cells were cultured and maintained in Dulbecco’s modi-
fied Eagle’s medium (DMEM) high glucose with 10% FCS, 4 mM 
glutamine, 1 mM sodium pyruvate, and 1× penicillin/streptomycin. 
RICTOR KO cells were generated as described by Bossler et al. (45). 
Four micrograms of plasmids harboring RICTOR-WT, RICTOR-A_3, 
and RICTOR-A_5 was transfected with jetPRIME (Polyplus). 
Twenty-four hours after transfection, cells were starved for serum 
for overnight and stimulated with 10% FCS and 100 nM insulin for 
15 min. Total cell lysates were prepared in lysis buffer containing 
100 mM tris-HCl (pH 7.5), 2 mM EDTA, 2 mM EGTA, 150 mM 
NaCl, 1% Triton X-100, complete inhibitor cocktail (Roche), and 
PhosSTOP (Roche). Protein concentration was determined by a 
Bradford assay, and equal amounts of protein were separated by 
SDS–polyacrylamide gel electrophoresis (SDS-PAGE) and trans-
ferred onto nitrocellulose membranes (GE Healthcare). Antibodies 
used were as follows: AKT (1:1000 dilution, catalog no. 2920, Cell 
Signaling Technology), AKT-pS473 (1:1000, catalog no. 4060, 
Cell Signaling Technology), RICTOR (1:1000, catalog no. 2040, 
Cell Signaling Technology), ACTIN (1:2000, catalog no. MAB1501, Mil-
lipore), IRDye 800CW goat anti-rabbit immunoglobulin G (IgG) 
(1:20,000, catalog no. 926-32211, LI-COR), and IRDye 680RD goat 
anti-mouse IgG (1:20,000, catalog no. 926-68070). All antibodies were 
 on N
ovem
ber 13, 2020
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
Scaiola et al., Sci. Adv. 2020; 6 : eabc1251     6 November 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
7 of 10
diluted in 10 ml of TBST and Licor intercept (TBS) blocking buffer 
(1:1). Signals were detected by LI-COR Fc (LI-COR Biosciences).
In-cell analysis of the dependence of mTORC2 activity 
on IPPK and MINPP1
HEK293T cells were cultured and maintained in DMEM high glu-
cose with 10% FCS, 4 mM glutamine, 1 mM sodium pyruvate, and 
1× penicillin/streptomycin. For KD of IPPK and MINPP1, 0.1 × 106 
cells per well were seeded in a six-well plate and transfected with 
100 nM small interfering RNA (siRNA) using the jetPRIME (Polyplus) 
system. After 32 hours, cells were washed twice with phosphate- 
buffered saline (PBS) (−/−) and starved for serum for 16 hours. 
Forty-eight hours after transfection, cells were incubated at 37°C 
with PBS (+/+) for 10 min followed by stimulation with 10% FCS 
and 100 nM insulin for 15 min at 37°C. Cells were washed with ice-
cold PBS (−/−) and harvested for SDS-PAGE or RNA isolation for 
quantitative polymerase chain reaction (qPCR) analysis. KO exper-
iments were conducted as described above, using generated KO cells 
instead of transfection with siRNA. Total cell lysates were prepared 
in M-PER lysis buffer (Thermo Fisher Scientific) containing com-
plete inhibitor cocktail (Roche) and PhosSTOP (Roche), and protein 
concentrations were determined by Bradford assay. Equal amounts 
of protein were separated by SDS-PAGE and transferred onto nitro-
cellulose membranes (GE Healthcare), and signals were detected by 
LI-COR Fc (LI-COR Biosciences). Antibodies used were as follows: 
AKT (1:1000, catalog no. 2920, Cell Signaling Technology), AKT-
pS473 (1:1000, catalog no. 4060, Cell Signaling Technology), ACTIN 
(1:5000, catalog no. MAB1501, Millipore), IRDye 800CW goat 
anti-rabbit IgG (1:20,000, catalog no. 926-32211, LI-COR), and 
IRDye 680RD goat anti-mouse IgG (1:20,000, catalog no. 926-68070). 
All antibodies were diluted in 10 ml of TBST and Licor intercept 
(TBS) blocking buffer (1:1).
For qPCR, total RNA was isolated using the RNeasy Kit (Qiagen). 
RNA was reverse-transcribed to complementary DNA (cDNA) using 
the iScript cDNA Synthesis Kit (Bio-Rad). Semiquantitative real- 
time PCR analysis was performed using Fast SYBR Green (Applied 
Biosystems). Relative expression levels were determined by normaliz-
ing each CT values to POLR2A using the ∆∆CT method. The sequence 
for the primers used in this study was as follows: IPPK-fw, 5′-AAT-
GAATGGGGGTACCACGG-3′; IPPK-rv, 5′-AACTTCAGAAAC-
CGCAGCAC-3′; MINPP1-fw, 5′-AGCTACTTTGCAAGTGCCAG-3′; 
MINPP1-rv, 5′-TGCATGACCAAACTGGAGGA-3′.
KO cells were generated using the LentiCRISPR system as de-
scribed by Sanjana et al. (46). Guide RNAs (gRNAs) against IPPK 
and MINPP1 were expressed from LentiCRISPRv2 (gifts from 
F. Zhang; Addgene plasmid nos. 49535 and 52961) by transfection 
of HEK293T cells with 1 g of DNA using jetPRIME. The following 
gRNA target sequences were used: IPPK gRNA, 5′-TCGGCCGGT-
GCTCTGCAAAG-3′; MINPP1 gRNA, 5′-ATCCAGTCCGCG-
TACCACAA-3′. Following transfection, cells were selected with 
puromycin, propagated, and screened for loss of target protein by 
qPCR. DNA sequencing of PCR products confirmed insertions or 
deletions leading to interrupted sequencing reactions. Pools of KO 
cells were used to avoid clonal variation. HEK293T cells transfected 
with empty vector were used as control.
Sample preparation for LC-MS analysis
Ten micrograms of mTORC2 I-site mutants I2 and I3 and A-site 
mutants A3, A4, and A5 was dissolved in 50 l of digestion buffer 
[1% sodium deoxycholate (SDC), 0.1 M tris, 10 mM TCEP, 15 mM 
chloroacetamide (CAA) (pH 8.5)] using vortexing for trypsin diges-
tion. For endoproteinase GluC and chymotrypsin digestion, the 
same protein aliquots were dissolved in 20 l of a digestion buffer 
consisting of 1 M urea, 0.1 M ammonium bicarbonate, 10 mM 
TCEP, and 15 mM CAA. Samples were either incubated for 10 min 
at 95°C (trypsin) or 1 hour at 37°C (GluC and chymotrypsin) to 
reduce and alkylate disulfide bonds. Protein aliquots were digested 
overnight at 37°C by incubation with sequencing-grade modified 
trypsin, GluC, and chymotrypsin (all 1:50, w/w; Promega). Then, 
the peptides were cleaned up using iST cartridges (PreOmics, 
Munich) according to the manufacturer’s instructions. Samples were 
dried under vacuum and dissolved in LC-buffer A (0.1% formic 
acid) at a concentration of 0.05 g/l.
Targeted parallel reaction monitoring–LC-MS analysis 
to confirm the presence of mutations
To enhance the sensitivity of the liquid chromatography–MS (LC-
MS) analysis, a label-free targeted LC-MS approach was carried out. 
Therefore, three lists of peptides considering the cleavage specificity 
of the three proteases used and containing all mutation sites were 
generated. The peptide sequences were imported into Skyline (ver-
sion 20.1; https://brendanx-uw1.gs.washington.edu/labkey/project/
home/software/Skyline/begin.view) to generate a mass isolation list 
of all doubly and triply charged precursor ions for each protease. 
These were then loaded into a Q Exactive plus LC-MS platform and 
analyzed using the following settings: The setup of the RPLC-MS 
system was as described previously (47). Chromatographic separa-
tion of peptides was carried out using an EASY nano-LC 1000 sys-
tem (Thermo Fisher Scientific), equipped with a heated RP-HPLC 
column (75 m by 30 cm) packed in-house with 1.9-m C18 resin 
(Reprosil-AQ Pur, Maisch). Peptides were analyzed per LC-MS/MS 
run using a linear gradient ranging from 95% solvent A (0.15% for-
mic acid and 2% acetonitrile) and 5% solvent B (98% acetonitrile, 
2% water, and 0.15% formic acid) to 45% solvent B over 60 min at a 
flow rate of 200 nl/min. MS analysis was performed on a Q Exactive 
plus mass spectrometer equipped with a nano-electrospray ion source 
(both Thermo Fisher Scientific). Each MS cycle consisted of one 
MS1 scan followed by high-collision dissociation of the selected 
precursor ions in the isolation mass lists. Total cycle time was 
approximately 2 s. For MS1, 3 × 106 ions were accumulated in the 
Orbitrap cell over a maximum time of 50 ms and scanned at a reso-
lution of 35,000 FWHM [at 200 mass/charge ratio (m/z)]. MS2 scans 
were acquired at a target setting of 3 × 106 ions, accumulation time 
of 110 ms, and a resolution of 35,000 FWHM (at 200 m/z). The nor-
malized collision energy was set to 27%, the mass isolation window was 
set to 0.4 m/z, and one microscan was acquired for each spectrum.
The acquired raw files were converted to the mascot generic 
file (mgf) format using the msconvert tool [part of ProteoWizard, 
version 3.0.4624 (2013-6-3)]. Using the MASCOT algorithm (Matrix 
Science, version 2.4.1), the mgf files were searched against a decoy 
database containing normal and reverse sequences of the predicted 
SwissProt entries of Homo sapiens (www.ebi.ac.uk, release date 
9 December 2019), the mTOR and Rictor mutations, and commonly 
observed contaminants (in total 41,556 sequences for H. sapiens) 
generated using the SequenceReverser tool from the MaxQuant 
software (version 1.0.13.13). The precursor ion tolerance was set to 
10 ppm, and fragment ion tolerance was set to 0.02 Da. The search 
criteria were set as follows: Full tryptic specificity was required 
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(cleavage after lysine or arginine residues unless followed by proline), 
three missed cleavages were allowed, carbamidomethylation (C) was 
set as a fixed modification, and oxidation (M) was set as a variable 
modification. Next, the database search results were imported to the 
Scaffold Q+ software (version 4.3.2, Proteome Software Inc., Portland, 
OR), and the protein false identification rate was set to 1% based on 
the number of decoy hits. Specifically, peptide identifications were 
accepted if they could be established at greater than 97.0% probability to 
achieve a false discovery rate less than 1.0% by the scaffold local FDR 
algorithm. Protein identifications were accepted if they could be es-
tablished at greater than 65.0% probability to achieve an FDR less 
than 1.0% and contained at least one identified peptide. Protein proba-
bilities were assigned by the Protein Prophet program (48). Proteins 
that contained similar peptides and could not be differentiated based 
on MS/MS analysis alone were grouped to satisfy the principles of 
parsimony. Proteins sharing significant peptide evidence were 
grouped into clusters. Last, a spectral library (*.blib) was generated 
from the assigned MS/MS spectra and imported to Skyline together 
with the acquired raw data files. Only precursor ions confidently 
identified by database searching and present in the spectral library 
were used for quantitative analysis. Quantitative result reports 
were further analyzed by Microsoft Excel and PRISM (GraphPad 
Software, San Diego, USA).
EM sample preparation and data collection
Different conditions were screened for mTORC2 in the presence 
and absence of substrates (fig. S2). For all conditions, freshly thawed 
mTORC2 aliquots were used to prepare samples with an mTORC2 
concentration of 0.37 mg/ml. Shortly before grid preparation, the 
samples were diluted to reach a final mTORC2 concentration of 
0.12 mg/ml.
For each grid, a small piece of continuous carbon was floated 
on top of the sample for 1 min. The carbon was then picked with a 
Quantifoil R2/2 holey carbon copper grid (Quantifoil Micro Tools), 
which was swiftly mounted in a Vitrobot (Thermo Fischer Scientific) 
whose chamber was set to 4°C and 100% humidity. Five microliters 
of buffer was then added on top of the grid on the side showing the 
carbon covered with particles, which was immediately blotted with 
a setting of 0- to 6-s blotting time and rapidly plunge-frozen in a 
mixture 2:1 of propane:ethane (Carbagas).
Data were collected using a Titan Krios (Thermo Fisher Scientific) 
transmission electron microscope equipped with either a K2 Summit 
direct electron detector (Gatan), a K3 direct electron detector 
(Gatan), or a Falcon 3EC direct electron detector (Thermo Fisher 
Scientific) using either EPU (Thermo Fisher Scientific) or SerialEM 
(fig. S2) (49). Cameras were used in counting and/or super-resolution 
mode. During data collection, the defocus was varied between −1 
and −3 m and four exposures were collected per holes. Stacks of 
frames were collected with a pixel size of 0.84 Å/pixel and a total 
dose of about 70 e−/Å2.
Data processing
For all datasets, the initial processing was done in similar fashion. 
First, the stacks of frames were aligned and dose-weighted using 
Motioncor2 (50). GCTF (51) was used to estimate the contrast 
transfer function (CTF) of the non–dose-weighted micrographs. 
After a selection of good micrographs using both the quality of 
the power spectra and the quality of the micrographs themselves as 
criteria, particles were picked using batchboxer from the EMAN1.9 
package (52) using particle averages from manually picked particles 
as references. Particles were extracted using Relion3.0 (53), fol-
lowed by two rounds of two-dimensional (2D) classification using 
cryoSPARCv2 (Structura Biotechnology Inc.) (table S2) (54). The 
first reference was generated by ab initio reconstruction using 
cryoSPARCv2. Good particles from 2D classification were then 
used for a homogeneous 3D refinement followed by nonuniform 
refinement using cryoSPARCv2. Two masks were then generated 
manually around each half of the pseudo-dimeric mTORC2 
using UCSF Chimera (55), and two focused refinements around 
each half of the complex using cryoSPARCv2 were performed 
using those masks. For dataset 1, which contained PH-Akt1, 
the resolution was further improved by performing Bayesian 
particle polishing (53) followed by CTF refinement using Relion3.1. 
Those particles were again subjected to a round of nonuniform 
refinement and local refinement using cryoSPARC v2. For each 
reconstruction, the maps were sharpened using phenix.auto_sharpen 
(56) or were transformed to structure factors using phenix.map_to_
structure_factors (56) and sharpened in COOT (57).
Further 3D classifications without alignment for local structural 
variability close to the catalytic center were performed using the 
particles from the datasets containing the purified Akt1 and, inde-
pendently, the ones from the dataset with PH-Akt1 using Relion3.0 
(53) and using a mask manually created in UCSF Chimera (55). 
After classification, the particles were used for refinement using 
cryoSPARCv2 (Structura Biotechnology Inc.). To compare the 
density of the sample with and without ATPS, the final density 
(volume A) was filtered to 4.2 Å and compared to the density with-
out ATPS (volume F). Difference density was calculated using 
UCSF ChimeraX (58).
Modeling and docking
First, mTOR and mLST8 models were taken from the EM structure 
of mTORC2 [Protein Data Bank (PDB): 5ZCS (20)] and each fold 
was rigid body–fitted into the better half of the density. Minor 
changes in mTOR conformation were done manually to fit the den-
sity, and then Rictor and SIN1 were manually built de novo using 
COOT (57). Map quality enabled direct model building for struc-
tured regions, and lower-resolution density provided connectivity 
information for assigning and linking regions of Sin1 and Rictor as 
shown in figs. S4C and S5B. The second half of mTORC2 was made 
by copying and rigid body fitting each chain of the first half in the 
second one. Last, the structure of either one- or two-sided mTORC2 
was refined using phenix.real_space_refine (table S2) (56), using 
Ramachandran and secondary structure restraints. As the horns of 
mTOR were flexible and their local resolutions were considerably 
lower, additional reference restraints were applied, using PDB: 6BCX 
(23) as reference. The model was then validated by comparing 
the Fourier Shell Correlations (FSC) calculated for the experi-
mental density and the models (fig. S3). In addition, both the half 
and full structure were also refined in their respective half map 
(half map 1) and the FSCs of this structure against the same half 
map (half map 1), the other half (half map 2), and the full map were 
compared. The similarity of the curves shows that the structure was 
not overfitted.
Ligand identification via MS
InsP6 (Sigma-Aldrich) was directly dissolved in 10 mM ammonium 
acetate (pH 8.5) and diluted to 50 M. mTORC2 in cryo-EM buffer 
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was buffer-exchanged and concentrated in 10 mM ammonium ace-
tate (pH 8.5) using an Amicon Ultra-0.5 mL—MWCO 100kDa. The 
concentrated complex was mixed with an equal volume of Phenol at 
pH 8, thoroughly vortexed for 30 s, and incubated at room tempera-
ture for 30 min. The tube was then centrifuged for 5 min at 15,000g. 
The aqueous phase was then used for MS. A sample containing only 
buffer and no protein was subjected to the same treatment for refer-
ence. The samples were then mixed with four volumes of injection 
buffer [90% acetonitrile, 9% methanol, 50 mM ammonium acetate 
(pH 7)] and directly injected using a Hamilton syringe in Synapt 
G2-SI HDMS (Waters) in negative mode and using the T-Wave IMS.
Figure generation
All density and structure representations were generated using UCSF 
ChimeraX (58). Difference densities were calculated in ChimeraX 
using the “volume subtract” command. Local resolutions were esti-
mated using cryoSPARC v2 (Structura Biotechnology Inc.). The 
electrostatic surface representation of Rictor was generated using 
APBS [Adaptive Poisson-Boltzmann Solver (59)]. Multiple sequence 
alignment was performed using Clustal Omega (60) and visualized 
with Espript (61). Conservation analysis was done with AL2CO (62) 
and visualized in UCSF ChimeraX (58).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/45/eabc1251/DC1
View/request a protocol for this paper from Bio-protocol.
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